Mutual of America Capital Management LLC Has $3.68 Million Holdings in Omnicell, Inc. $OMCL

Mutual of America Capital Management LLC increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 4.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 125,286 shares of the company’s stock after acquiring an additional 5,585 shares during the quarter. Mutual of America Capital Management LLC owned 0.27% of Omnicell worth $3,683,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in OMCL. GAMMA Investing LLC raised its holdings in shares of Omnicell by 37.1% during the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock valued at $50,000 after acquiring an additional 458 shares during the period. AlphaQuest LLC raised its holdings in shares of Omnicell by 79.0% during the first quarter. AlphaQuest LLC now owns 6,400 shares of the company’s stock valued at $224,000 after acquiring an additional 2,824 shares during the period. New Age Alpha Advisors LLC purchased a new position in Omnicell during the first quarter valued at approximately $233,000. EntryPoint Capital LLC grew its position in Omnicell by 21.6% during the first quarter. EntryPoint Capital LLC now owns 6,671 shares of the company’s stock valued at $233,000 after purchasing an additional 1,184 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Omnicell by 7.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,040 shares of the company’s stock valued at $236,000 after purchasing an additional 552 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Performance

OMCL stock opened at $30.89 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 61.78, a P/E/G ratio of 6.47 and a beta of 0.88. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The firm has a 50 day moving average of $31.45 and a two-hundred day moving average of $30.21.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.30 by $0.15. The company had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Analyst Ratings Changes

OMCL has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Piper Sandler lowered their price objective on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 11th. Wells Fargo & Company boosted their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, July 21st. Finally, Wall Street Zen downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $46.71.

Insider Buying and Selling

In related news, EVP Corey J. Manley sold 3,880 shares of the company’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the completion of the sale, the executive vice president directly owned 110,653 shares of the company’s stock, valued at approximately $3,679,212.25. This represents a 3.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.52% of the stock is owned by corporate insiders.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.